Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis

Moxifloxacin is currently recommended at a dose of 7.5-10 mg/kg for children with multidrug-resistant (MDR) tuberculosis, but pharmacokinetic and long-term safety data of moxifloxacin in children with tuberculosis are lacking. An area under the curve (AUC) of 40-60 µg × h/mL following an oral moxifl...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical infectious diseases Ročník 60; číslo 4; s. 549
Hlavní autoři:	Thee, Stephanie, Garcia-Prats, Anthony J, Draper, Heather R, McIlleron, Helen M, Wiesner, Lubbe, Castel, Sandra, Schaaf, H Simon, Hesseling, Anneke C
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 15.02.2015
Témata:	Adolescent Antibiotics, Antitubercular - administration & dosage Antibiotics, Antitubercular - adverse effects Antibiotics, Antitubercular - blood Antibiotics, Antitubercular - pharmacokinetics Area Under Curve Child Drug Tolerance Female Fluoroquinolones - administration & dosage Fluoroquinolones - adverse effects Fluoroquinolones - blood Fluoroquinolones - pharmacokinetics Half-Life HIV Infections - complications Humans Male Prospective Studies South Africa Tuberculosis, Multidrug-Resistant - complications Tuberculosis, Multidrug-Resistant - drug therapy South Africa children moxifloxacin toxicity MDR tuberculosis moxifloxacin pharmacokinetics
ISSN:	1537-6591, 1537-6591
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!